Inventor profile of:

Judith Campisi

City:

Berkeley, California

Country:

United States

Published Applications:

40

Last publication date:

2024-04-11

Top Assignees for applications by Judith Campisi

The entities that hold a legal rights for patent applications filed by inventor Campisi Judith:

Recent patent applications by Campisi Judith

Judith Campisi from Berkeley, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-04-11
US20240115563A1
Human necessities

Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor

#2 | 2022-07-21
US20220228213A1
Chemistry; metallurgy

Biomarkers for detecting senescent cells

#3 | 2022-03-31
US20220096466A1
Human necessities

TREATMENT OF PARKINSON'S DISEASE AND OTHER CONDITIONS CAUSED OR MEDIATED BY SENESCENT ASTROCYTES USING SMALL MOLECULE SENOLYTIC AGENTS

#4 | 2021-06-10
US20210169876A1
Human necessities

Treating liver disease by selectively eliminating senescent cells

#5 | 2021-06-10
US20210169875A1
Human necessities

Treating cardiovascular disease by selectively eliminating senescent cells

#6 | 2021-02-04
US20210030752A1
Human necessities

TREATING COGNITIVE DECLINE AND OTHER NEURODEGENERATIVE CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM NEUROLOGICAL TISSUE

#7 | 2020-11-26
US20200371122A1
Physics

BIOMARKER FOR SENESCENT CELLS

#8 | 2020-01-30
US20200030323A1
Human necessities

Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue

#9 | 2019-11-14
US20190343832A1
Human necessities

THERAPY FOR REMOVING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED DISEASE USING AN MDM2 INHIBITOR

#10 | 2019-07-04
US20190201510A1
Human necessities

PASSIVE VACCINE FOR ELIMINATION OF SENESCENT CELLS

#11 | 2019-01-24
US20190022090A1
Human necessities

Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

#12 | 2019-01-03
US20190000846A1
Human necessities

Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression

#13 | 2018-10-25
US20180303828A1
Human necessities

Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss

#14 | 2018-09-13
US20180256568A1
Human necessities

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase

#15 | 2018-08-23
US20180235957A1
Human necessities

Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye

#16 | 2018-08-23
US20180235956A1
Human necessities

Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen

#17 | 2018-07-12
US20180193458A1
Human necessities

COMPOSITIONS AND METHODS FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

#18 | 2018-05-24
US20180139939A1
Human necessities

Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells

#19 | 2018-05-03
US20180117038A1
Human necessities

Treatment of ophthalmic conditions by selectively removing senescent cells from the eye

#20 | 2018-04-19
US20180104222A1
Human necessities

Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques

#21 | 2017-12-07
US20170348307A1
Human necessities

Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease

#22 | 2017-11-16
US20170326136A1
Human necessities

Treatment of joint pain

#23 | 2017-08-10
US20170224680A2
Human necessities

Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2

#24 | 2017-07-27
US20170209435A1
Human necessities

Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline

#25 | 2017-07-13
US20170198253A1
Chemistry; metallurgy

Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population

#26 | 2017-07-13
US20170196858A1
Human necessities

METHODS AND COMPOSITIONS FOR KILLING SENESCENT CELLS AND FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

#27 | 2017-07-13
US20170196857A1
Human necessities

Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells

#28 | 2017-05-04
US20170119789A1
Human necessities

Inhibiting activity of senescent cells using a glucocorticoid

#29 | 2017-02-16
US20170042129A1
Human necessities

Transgenic mouse for determining the role of senescent cells in cancer

#30 | 2017-02-02
US20170027139A1
Human necessities

Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells

#31 | 2016-11-24
US20160339019A1
Human necessities

METHODS AND COMPOSITIONS FOR KILLING SENESCENT CELLS AND FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

#32 | 2016-02-11
US20160038576A1
Human necessities

Immunogenic compositions for inducing an immune response for elimination of senescent cells

#33 | 2014-11-13
US20140335074A1
Human necessities

METHODS FOR IMPROVING MEDICAL THERAPIES

#34 | 2013-10-31
US20130288981A1
Human necessities

TARGETING SENESCENT CELLS AND CANCER CELLS BY INTERFERENCE WITH JNK AND/OR FOXO4

#35 | 2013-10-31
US20130288980A1
Chemistry; metallurgy

TARGETING SENESCENT AND CANCER CELLS FOR SELECTIVE KILLING BY INTERFERENCE WITH FOXO4

#36 | 2012-01-26
US20120021047A1
Chemistry; metallurgy

gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma

#37 | 2009-07-16
US20090180988A1
Chemistry; metallurgy

and genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma

#38 | 2008-09-30
US9952534
-

Id-1 and Id-2 genes and products as markers of epithelial cancer

#39 | 2006-11-23
US20060263809A1
Physics

Method for sensitive measure of low level apoptosis in cells

#40 | 2006-10-19
US20060234273A1
Chemistry; metallurgy

Id-1 and Id-2 genes and products as markers of epithelial cancer

InventorID:

509510 ⎘